119 related articles for article (PubMed ID: 24295567)
1. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation.
Dicitore A; Caraglia M; Gaudenzi G; Manfredi G; Amato B; Mari D; Persani L; Arra C; Vitale G
Biochim Biophys Acta; 2014 Jan; 1845(1):42-52. PubMed ID: 24295567
[TBL] [Abstract][Full Text] [Related]
2. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
Vitale G; Zappavigna S; Marra M; Dicitore A; Meschini S; Condello M; Arancia G; Castiglioni S; Maroni P; Bendinelli P; Piccoletti R; van Koetsveld PM; Cavagnini F; Budillon A; Abbruzzese A; Hofland LJ; Caraglia M
Biotechnol Adv; 2012; 30(1):169-84. PubMed ID: 21871555
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy?
Dicitore A; Caraglia M; Colao A; Zappavigna S; Mari D; Hofland LJ; Persani L; Vitale G
Curr Cancer Drug Targets; 2013 May; 13(4):460-71. PubMed ID: 23617255
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system.
Sawai H; Liu J; Reber HA; Hines OJ; Eibl G
Mol Cancer Res; 2006 Mar; 4(3):159-67. PubMed ID: 16547153
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
[TBL] [Abstract][Full Text] [Related]
6. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NF kappaB pathway.
Kim EK; Kwon KB; Koo BS; Han MJ; Song MY; Song EK; Han MK; Park JW; Ryu DG; Park BH
Int J Biochem Cell Biol; 2007; 39(6):1260-75. PubMed ID: 17521952
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
Sun WH; Chen GS; Ou XL; Yang Y; Luo C; Zhang Y; Shao Y; Xu HC; Xiao B; Xue YP; Zhou SM; Zhao QS; Ding GX
Cancer Lett; 2009 Mar; 275(2):247-55. PubMed ID: 19056168
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway.
Seo SK; Seo DI; Park WS; Jung WK; Lee DS; Park SG; Choi JS; Kang MS; Choi YH; Choi I; Yu BC; Choi IW
Life Sci; 2014 Sep; 112(1-2):82-9. PubMed ID: 25072357
[TBL] [Abstract][Full Text] [Related]
10. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.
Vitale G; van Eijck CH; van Koetsveld Ing PM; Erdmann JI; Speel EJ; van der Wansem Ing K; Mooij DM; Colao A; Lombardi G; Croze E; Lamberts SW; Hofland LJ
Ann Surg; 2007 Aug; 246(2):259-68. PubMed ID: 17667505
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of type I interferon signaling in normal and malignant cells.
Li Y; Srivastava KK; Platanias LC
Arch Immunol Ther Exp (Warsz); 2004; 52(3):156-63. PubMed ID: 15247882
[TBL] [Abstract][Full Text] [Related]
12. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells.
Zitzmann K; Brand S; De Toni EN; Baehs S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
Cancer Res; 2007 May; 67(10):5025-32. PubMed ID: 17510435
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC).
Bren-Mattison Y; Van Putten V; Chan D; Winn R; Geraci MW; Nemenoff RA
Oncogene; 2005 Feb; 24(8):1412-22. PubMed ID: 15608671
[TBL] [Abstract][Full Text] [Related]
14. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
15. 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells.
Chintharlapalli S; Papineni S; Liu S; Jutooru I; Chadalapaka G; Cho SD; Murthy RS; You Y; Safe S
Carcinogenesis; 2007 Nov; 28(11):2337-46. PubMed ID: 17724373
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.
Keshamouni VG; Reddy RC; Arenberg DA; Joel B; Thannickal VJ; Kalemkerian GP; Standiford TJ
Oncogene; 2004 Jan; 23(1):100-8. PubMed ID: 14712215
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between peroxisome proliferator activator-receptor (PPAR) and urological cancer].
Yoshimura R; Nakatani T
Nihon Rinsho; 2005 Apr; 63(4):672-8. PubMed ID: 15828236
[TBL] [Abstract][Full Text] [Related]
19. hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
Li Y; Wen X; Spataro BC; Hu K; Dai C; Liu Y
J Am Soc Nephrol; 2006 Jan; 17(1):54-65. PubMed ID: 16291834
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
